These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

452 related articles for article (PubMed ID: 25760637)

  • 41. Anti-CD30 CAR T cells as consolidation after autologous haematopoietic stem-cell transplantation in patients with high-risk CD30
    Grover NS; Hucks G; Riches ML; Ivanova A; Moore DT; Shea TC; Seegars MB; Armistead PM; Kasow KA; Beaven AW; Dittus C; Coghill JM; Jamieson KJ; Vincent BG; Wood WA; Cheng C; Morrison JK; West J; Cavallo T; Dotti G; Serody JS; Savoldo B
    Lancet Haematol; 2024 May; 11(5):e358-e367. PubMed ID: 38555923
    [TBL] [Abstract][Full Text] [Related]  

  • 42. BEAM or BuCyE high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients: a single center comparative analysis of efficacy and toxicity.
    Kim JE; Lee DH; Yoo C; Kim S; Kim SW; Lee JS; Park CJ; Huh J; Suh C
    Leuk Res; 2011 Feb; 35(2):183-7. PubMed ID: 20684990
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Busulfan, etoposide, cytarabine, and melphalan as a high-dose regimen for autologous stem cell transplantation in peripheral T-cell lymphomas.
    Jo JC; Kim JS; Lee JH; Lee JH; Im SN; Lee SM; Yoon SS; Kim IH; Bae SH; Lee YJ; Choi Y; Lee WS
    Ann Hematol; 2021 Jan; 100(1):189-196. PubMed ID: 33205337
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Similar response rates and superior early progression-free survival with gemcitabine, dexamethasone, and cisplatin salvage therapy compared with carmustine, etoposide, cytarabine, and melphalan salvage therapy prior to autologous stem cell transplantation for recurrent or refractory Hodgkin lymphoma.
    Kuruvilla J; Nagy T; Pintilie M; Tsang R; Keating A; Crump M
    Cancer; 2006 Jan; 106(2):353-60. PubMed ID: 16329112
    [TBL] [Abstract][Full Text] [Related]  

  • 45. BEAC (carmustine, etoposide, cytarabine, and cyclophosphamide) in autologous hematopoietic cell transplantation: a safe and effective alternative conditioning regimen for Hodgkin and non-Hodgkin lymphoma.
    Sakellari I; Gavriilaki E; Bouziana S; Constantinou V; Mallouri D; Vardi A; Marvaki A; Batsis I; Sotiropoulos D; Anagnostopoulos A
    Bone Marrow Transplant; 2019 Jun; 54(6):921-923. PubMed ID: 30410083
    [No Abstract]   [Full Text] [Related]  

  • 46. Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients.
    Schmitz N; Linch DC; Dreger P; Goldstone AH; Boogaerts MA; Ferrant A; Demuynck HM; Link H; Zander A; Barge A
    Lancet; 1996 Feb; 347(8998):353-7. PubMed ID: 8598700
    [TBL] [Abstract][Full Text] [Related]  

  • 47. BEAC or BEAM high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients: comparative analysis of efficacy and toxicity.
    Jo JC; Kang BW; Jang G; Sym SJ; Lee SS; Koo JE; Kim JW; Kim S; Huh J; Suh C
    Ann Hematol; 2008 Jan; 87(1):43-8. PubMed ID: 17710401
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Carmustine, etoposide, cytarabine, and melphalan (BEAM)-campath allogeneic stem cell transplantation for aggressive non-hodgkin lymphoma: an analysis of outcomes from the British Society of Blood and Marrow Transplantation.
    Truelove E; Fox C; Robinson S; Pearce R; Perry J; Kirkland K; McQuaker G; Pagliuca A; Johnson P; Russell N; Cook G;
    Biol Blood Marrow Transplant; 2015 Mar; 21(3):483-8. PubMed ID: 25490180
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparison of CBV, BEAM and BEAC high-dose chemotherapy followed by autologous hematopoietic stem cell transplantation in non-Hodgkin lymphoma: Efficacy and toxicity.
    Shi Y; Liu P; Zhou S; Yang J; Han X; He X; Zhang C; Gui L; Qin Y; Yang S; Zhao L; Yao J; Jia B; Zhang S; Sun Y; Shi Y
    Asia Pac J Clin Oncol; 2017 Oct; 13(5):e423-e429. PubMed ID: 28101911
    [TBL] [Abstract][Full Text] [Related]  

  • 50. High-dose chemotherapy with BEAM or Busulphan/Melphalan and Thiotepa followed by hematopoietic cell transplantation in malignant lymphoma.
    Zaucha R; Gooley T; Holmberg L; Gopal AK; Press O; Maloney D; Bensinger WI
    Leuk Lymphoma; 2008 Oct; 49(10):1899-906. PubMed ID: 18949614
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Total Body Irradiation Is Safe and Similarly Effective as Chemotherapy-Only Conditioning in Autologous Stem Cell Transplantation for Mantle Cell Lymphoma.
    Tseng YD; Stevenson PA; Cassaday RD; Cowan A; Till BG; Shadman M; Graf SA; Ermoian R; Smith SD; Holmberg LA; Press OW; Gopal AK
    Biol Blood Marrow Transplant; 2018 Feb; 24(2):282-287. PubMed ID: 29061536
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinical and safety outcomes of BeEAM (Bendamustine, Etoposide, Cytarabine, Melphalan) versus CEM (Carboplatin, Etoposide, Melphalan) in lymphoma patients as a conditioning regimen before autologous hematopoietic cell transplantation.
    Eltelbanei MA; El-Bassiouny NA; Abdalla MS; Khalaf M; Werida RH
    BMC Cancer; 2024 Aug; 24(1):1002. PubMed ID: 39134959
    [TBL] [Abstract][Full Text] [Related]  

  • 53. High-dose therapy with BEAC conditioning compared to BEAM conditioning prior to autologous stem cell transplantation for non-Hodgkin lymphoma: no differences in toxicity or outcome. A matched-control study of the EBMT-Lymphoma Working Party.
    Robinson SP; Boumendil A; Finel H; Dreger P; Sureda A; Hermine O; Montoto S
    Bone Marrow Transplant; 2018 Dec; 53(12):1553-1559. PubMed ID: 29884850
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Single-center retrospective study assessing the efficacy and safety of BeEAM (bendamustine, etoposide, cytarabine, melphalan) as conditioning regimen for autologous hematopoietic stem cell transplantation.
    Plante MÉ; Feng X; Boudreault JS
    Leuk Lymphoma; 2023; 64(7):1234-1242. PubMed ID: 37154396
    [TBL] [Abstract][Full Text] [Related]  

  • 55. BEAM Conditioning Regimen Has Higher Toxicity Compared With High-Dose Melphalan for Salvage Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma.
    Veeraputhiran M; Jain T; Deol A; Ayash L; Kim S; Dyson G; Bhutani D; Lum LG; Ratanatharathorn V; Uberti JP; Abidi MH
    Clin Lymphoma Myeloma Leuk; 2015 Sep; 15(9):531-5. PubMed ID: 26166312
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Etoposide pharmacokinetics impact the outcomes of lymphoma patients treated with BEAM regimen and ASCT: a multicenter study of the LYmphoma Study Association (LYSA).
    You B; Salles G; Bachy E; Casasnovas O; Tilly H; Ribrag V; Sebban C; Hénin E; Guitton J; Tod M; Freyer G
    Cancer Chemother Pharmacol; 2015 Nov; 76(5):939-48. PubMed ID: 26391155
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Dexamethasone, carmustine, etoposide, cytarabine, and melphalan (dexa-BEAM) followed by high-dose chemotherapy and stem cell rescue--a highly effective regimen for patients with refractory or relapsed indolent lymphoma.
    Josting A; Reiser M; Wickramanayake PD; Rueffer U; Draube A; Söhngen D; Tesch H; Wolf J; Diehl V; Engert A
    Leuk Lymphoma; 2000 Mar; 37(1-2):115-23. PubMed ID: 10721775
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparison of efficacy and toxicity according to etoposide and cytarabine dosing in BEAM conditioning followed by autologous stem cell transplantation in Hodgkin lymphoma.
    Vély A; Couturier MA; Delepine P; Le Calloch R; Ertault M; Gastinne T; Plichon C; Lebreton A; Lester MA; Larhantec G; Cormier N; Fouquet S; Houot R; Tanguy-Schmidt A; Hunault-Berger M; Orvain C
    Leuk Lymphoma; 2023 Dec; 64(13):2178-2187. PubMed ID: 37615123
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pegfilgrastim appears equivalent to daily dosing of filgrastim to treat neutropenia after autologous peripheral blood stem cell transplantation in patients with non-Hodgkin lymphoma.
    Rifkin R; Spitzer G; Orloff G; Mandanas R; McGaughey D; Zhan F; Boehm KA; Asmar L; Beveridge R
    Clin Lymphoma Myeloma Leuk; 2010 Jun; 10(3):186-91. PubMed ID: 20511163
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas.
    Schütt P; Passon J; Ebeling P; Welt A; Müller S; Metz K; Moritz T; Seeber S; Nowrousian MR
    Eur J Haematol; 2007 Feb; 78(2):93-101. PubMed ID: 17313557
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.